Drug Delivery Device Comprising Silicon-Based Carrier Particles
This application provides a device for delivering a beneficial substance to a patient. The device comprises a shell enclosing a plurality of carrier particles. The carrier particles are porous, and a beneficial substance, such as a drug, is disposed in the pores. The drug can diffuse out of the pores, into the interior of the device, and then through at least one permeable portion of the shell. This application also provides methods of making and using these devices.
1 . A device comprising a shell and a plurality of particles disposed within the shell, the particles comprising a porous carrier material and a beneficial substance disposed within pores of the carrier, and the shell comprising at least one portion that is permeable to the beneficial substance.
2 . The device of claim 1 , wherein the shell comprises a polymer.
3 . The device of claim 1 , wherein the shell comprises:
a tube having first and second ends;
a first member positioned at the first end; and
a second member positioned at the second end;
wherein the particles are inside the tube and the first and second members retain the particles in the tube.
4 . (canceled)
5 . The device of claim 3 , wherein the tube is impermeable to the beneficial substance.
6 . The device of claim 5 , wherein the tube comprises poly(lactic-co-glycolic acid) (PLGA).
7 . The device of claim 3 , wherein the first member and second member are permeable to the beneficial substance.
8 . The device of claim 7 , wherein the first member and second member comprise poly(vinyl alcohol) (PVA).
9 . The device of claim 3 , wherein the first member is permeable to the beneficial substance and the second member is impermeable to the beneficial substance.
10 . The device of claim 9 , wherein the first member comprises poly(vinyl alcohol) (PVA).
11 . The device of claim 9 , wherein the second member comprises silicone.
12 . The device of claim 3 , wherein the tube has a length of between 1 and 4 mm.
13 . (canceled)
14 . The device of claim 1 , wherein the carrier material is mesoporous.
15 . (canceled)
16 . The device of claim 1 , wherein the carrier material is silicon-based.
17 . The device of claim 1 , wherein the carrier material comprises elemental silicon.
18 . The device of claim 1 , wherein the carrier material comprises silica.
19 . (canceled)
20 . The device of claim 1 , wherein the carrier material comprises anodized silicon.
21 . The device of claim 1 , wherein the carrier material is resorbable or bio-erodible.
22 . The device of claim 1 , wherein the particles have a d50 in the range of 5-10 microns.
23 . The device of claim 1 , wherein the device releases the beneficial substance at a release rate, the release rate being determined primarily by release of the beneficial substance from pores of the carrier material.
24 . The device of claim 1 , wherein, when the device is placed in a biological medium, the beneficial substance is released from the device according to a substantially zero-order release profile.
25 . The device of claim 1 , wherein the beneficial substance is selected from small molecules, proteins, peptides, antibodies, carbohydrates, lipids, polymers, oligonucleotides, and polynucleotides.
26 . The device of claim 1 , wherein the beneficial substance is ranibizumab or bevacizumab.
27 . A method of making a device, comprising:
(a) providing a tube having first and second ends;
(b) inserting a plurality of particles into the tube, wherein the particles comprise porous silicon-based carrier material;
(c) adding a first member to the first end of the tube; and
(d) adding a second member to the second end to the tube,
wherein at least one of the tube, the first member, and the second member is permeable to the beneficial substance.
28 - 33 . (canceled)
34 . A device manufactured by the method of claim 27 .
35 . A method of delivering a beneficial substance to a patient, comprising administering to a patient a device according to claim 1 , whereby the beneficial substance is released from the device into the patient after administration.
36 - 37 . (canceled)